Sugi Predict

Sugi Predict / Targets / PIK3C3

PIK3C3

Phosphatidylinositol 3-kinase catalytic subunit type 3 · Q8NEB9 · PIK3C3 on Sugi Atlas →

59,954 patent compounds predicted against PIK3C3, 35,558 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL84076 SCHEMBL84076 0.48 12/20
Wortmannin Wortmannin (SCHEMBL4530) 1.00 10/20
Wortmannin Wortmannin (SCHEMBL4531) 1.00 10/20
SCHEMBL84506 SCHEMBL84506 0.49 10/20
SCHEMBL91333 SCHEMBL91333 0.50 7/20
SCHEMBL48579 SCHEMBL48579 0.61 5/20
SCHEMBL48734 SCHEMBL48734 0.61 5/20
SCHEMBL48745 SCHEMBL48745 0.52 5/20
SCHEMBL49300 SCHEMBL49300 0.51 5/20
SCHEMBL48534 SCHEMBL48534 0.50 5/20
SCHEMBL48887 SCHEMBL48887 0.50 5/20
SCHEMBL48754 SCHEMBL48754 0.49 5/20
SCHEMBL48913 SCHEMBL48913 0.49 5/20
SCHEMBL48640 SCHEMBL48640 0.48 5/20
SCHEMBL48688 SCHEMBL48688 0.48 5/20
SCHEMBL48716 SCHEMBL48716 0.48 5/20
SCHEMBL48718 SCHEMBL48718 0.47 5/20
SCHEMBL48649 SCHEMBL48649 1.00 4/20
SCHEMBL48392 SCHEMBL48392 0.72 4/20
SCHEMBL48485 SCHEMBL48485 0.72 4/20

Clinical trials — most relevant to PIK3C3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder PHASE2/PHASE3RECRUITING
Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care PHASE3RECRUITING
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome PHASE1/PHASE2COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
New Individualized Therapy Trial for Metastatic Colorectal Cancer PHASE1/PHASE2COMPLETED
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N) PHASE2ACTIVE_NOT_RECRUITING
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) PHASE2ACTIVE_NOT_RECRUITING
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma PHASE2COMPLETED
Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Palliative Thoracic Radiotherapy Plus BKM120 PHASE1COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors PHASE1COMPLETED
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma PHASE1COMPLETED
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors nanUNKNOWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Studying Tumor Tissue Samples From Patients With Early-Stage Breast Cancer nanWITHDRAWN
New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ Syndrome nanRECRUITING
IL-17 Role in Variants of Psoriasis nanCOMPLETED
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia nanCOMPLETED
Exploring the Link Between Cancer Genetics and PPSP nanUNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia nanUNKNOWN
KRAS Mutation and Incidence of the Colorectal Carcinoma in Martinique Between 2007 and 2009 nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PIK3C3 binder may also engage these)

ProteinNameSimilarity
Q5D891 — 1.000 Q5D891 →
Q6PF93 — 1.000 Q6PF93 →
Q6AZN6 — 1.000 Q6AZN6 →
O88763 — 1.000 O88763 →
P42348 — 0.997 P42348 →
P42339 — 0.995 P42339 →
A0A0G2K344 — 0.992 A0A0G2K344 →
Q8BTI9 — 0.992 Q8BTI9 →
P42347 — 0.991 P42347 →
P32871 — 0.990 P32871 →
P50520 — 0.990 P50520 →
PIK3CA Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform 0.990 landscape →
P42337 — 0.990 P42337 →
O02697 — 0.989 O02697 →
PIK3CD Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform 0.989 landscape →
Q9TXI7 — 0.988 Q9TXI7 →
Q9JHG7 — 0.987 Q9JHG7 →
Q9Z1L0 — 0.987 Q9Z1L0 →
P22543 — 0.986 P22543 →
P54676 — 0.986 P54676 →
PIK3CG Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform 0.986 landscape →
Q86T65 — 0.986 Q86T65 →
Q24087 — 0.985 Q24087 →
P70600 — 0.985 P70600 →
B4NBB0 — 0.985 B4NBB0 →
PIK3CB Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform 0.984 landscape →
Q6FSR7 — 0.984 Q6FSR7 →
A0A2R8QPS5 — 0.984 A0A2R8QPS5 →
O35904 — 0.984 O35904 →
B0XDC4 — 0.984 B0XDC4 →